Sin categoría

US Allotropic Tech and Bionaturis Group join forces

Bionaturis Group and the US-biotech company Allotropic Tech has signed an agreement to work together in the development of biological products for pharmaceutical, petrochemical, nutritional, and cosmetic industries, among others. Allotropic Tech’s personnel are pioneers in the field of expression systems in insects such as FLYLIFE. 
According to Bionaturis Group’s CEO, Victor Infante, “with this agreement, Bionaturis Group continues adding up strategic alliances and improving its competitiveness. Allotropic’s team is composed of recognized experts at using insects to express difficult to obtain proteins, and therefore, one more value added for our clients and development partners. This agreement will also allow us to broaden our product portfolio”.
Allotropic’s CEO, Robert Balcerzak, has stated “we look forward to collaborating with Bionaturis in advancing the expression of proteins in insects and are particularly excited about drawing on Bionaturis’ worldwide sales presence”.
About Allotropic
Allotropic Tech is located in Baltimore MD USA with facilities located in the mid-Atlantic corridor region. Allotropic Tech has extensive experience supplying recombinant proteins with particular emphasis on supplying proteins to government laboratories, university research departments and corporate R&D departments.
About Bionaturis

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in the vaccines research, the biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).
 

December 4th, 2015|Blog english, Sin categoría|Comments Off|

Juan Juarez buys 5% of Bionaturis and Rafael Contreras increases his position

The strong Bionaturis (BNT. MC) commitment of consolidating its international growth strategy, presence and professionalization in the financial markets has become real with the appointment of Juan Juarez as a Board Member since last June, 30. As part of the operation, Juarez has acquired 5% of the biotech.

Juan Juarez, degree in Laws at Madrid University and in Economics at Madrid-ICADE, Master in Finance from the IE (Madrid) and Master in Financial Markets (Madrid Stock Exchange), besides of being part of management teams in banks and financial entities, is nowadays an executive and founding partner of companies as Privat und Handel Bank Zürich AG, Ad-Hoc Aesores EAFI SA and Juarez & Asociados –Family Office SA. Juarez is also member of the Board of Directors and financial vice-president at Carbures Group and he is considered a key person in the outstanding growth of the company of composite structures, that has already announced its goal of start quoting soon in the continuous market.

The strategic movement is completed with the increase of shareholding position by Rafael Contreras, member of the Boards of Directors of the biotech company since 2011. Rafael Contreras, in a direct and indirect way, increases his ownership up to 7,5%. Contreras is CEO at Carbures Group and is leading its outperforming international expansion.

As it has been published as Relevant Fact, Victor Infante, CEO and Bionaturis main shareholder, has reduced its participation until 43,06%, as a result of the abovementioned movement. About the operation, Victor Infante has stated: “Bionaturis gains unbeatable conditions to fulfill our growth plan. Their track record in Carbures Group has been impressive”.

The exchanged shares shall keep the original lock-up, held to CEO´s shares.

 

About Carbures

Carbures is an industrial technological group specialized in manufacturing […]

July 8th, 2014|Sin categoría|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR